Price data is not available
VolitionRX Ltd
VNRXAMEX
VolitionRX fell 97.6% from $7.60 to $0.18, behind the S&P 500's +9.8%. Its worst day was Jun 8 (−22.3%), and its low came Oct 21 at $0.17.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-1.00 beat the $-1.00 estimate on $627,277.00 revenue (est. $1.6M).
−6.6% · S&P 500 0.0%
Story events cover the past 12 months · Times ET
Paves the Way for World’s First Feline Liquid Biopsy Test for Cancer DetectionHENDERSON, Nev., Jan.
+24.2% · S&P 500 0.0%
VolitionRX shares rose 25.6%, while the S&P 500 rose 0.8%.
+25.6% · S&P 500 +0.8%
EPS of $-1.00 missed the $-0.80 estimate on $447,034.00 revenue (est. $780,106.00).
−1.0% · S&P 500 +0.8%
EPS of $-0.97 missed the $-0.73 estimate on $985,076.00 revenue (est. $425,936.00).
−9.1% · S&P 500 −1.2%
VolitionRX shares fell 22.3%, while the S&P 500 rose 0.2%.
−22.3%, the year's worst day · S&P 500 +0.2%
EPS of $-0.85 missed the $-0.68 estimate on $398,657.00 revenue (est. $489,472.00).
−14.8% · S&P 500 −0.2%
VolitionRx reports 112% revenue growth in H1 2026 while advancing its Nu.Q diagnostic platforms across sepsis and oncology markets.
+47.7%, the year's best day, on 354M shares, the year's heaviest volume · S&P 500 +0.7%
VolitionRX closed at its lowest level of the year, 97.8% below where the year started.
−3.9% · S&P 500 +0.5%
Where it ended: a close of $0.18 on Nov 10, 2026. Up next: Q3 2026 earnings on Nov 12, 2026 (EPS est. $-0.32, revenue est. $788,920.00).
Nothing in the past 12 months.
All VNRX dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for VNRX and SPY from Benzinga historical bars. Not investment advice.
